Total votes: 5

Stirling Products Limited (Stirling) is engaged in the development and commercialization of a range of animal growth promoters that redirect energy from fat production to protein (meat), while also improving feed efficiency. The Company is also developing therapeutic medications for heaves in horses and a treatment for obesity in companion animals and humans. Stirling’s four operational divisions comprise: human healthcare products; animal healthcare products; direct marketing, and product manufacturing. During the fiscal year ended June 30, 2009, Stirling entered into a joint venture with Zodiac Capital Limited to commercialize a range of developed phyto-pharmaceuticals. As of June 30, 2009, Stirling had terminated all its interests in the intellectual property and business for the delivery of inhalation compounds to horses (Pulmovet ApS) and fortified waters for companion animals (Stirling Animal Health).

TeleMedicine
A new endeavour for thecompany is into Telemedicine via a August 2010 deal where Stirling acquired a 65% controlling interest in remote patient monitoring equipment company TeleMedCare Holdings Pty Ltd, which is in administration. TeleMedCare operates in Australia and the UK but intends to expand in other countries.

Creditors of TeleMedCare and a wholly-owned subsidiary have approved deeds of company arrangement (DOCAs) which provide for Stirling to contribute a total $511,302 over the next 12 months (from Aug 2010) as full settlement of the TeleMedCare group trade creditors. Stirling will also provide $3 million in working capital over 18 months, and allow for the repayment of shareholder loans of $3.66 million exclusively from future TeleMedCare profits.